Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NN1218 · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| NN1218, formulation A | EXPERIMENTAL | - |
| NN1218, formulation B | EXPERIMENTAL | - |
| NN1218, formulation B (high) | EXPERIMENTAL | - |
| NN1218, formulation C | EXPERIMENTAL | - |
| NN1218, formulation D | EXPERIMENTAL | - |
| insulin aspart | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| NN1218 | DRUG | 0.2 U/kg body weight injected subcutaneously (under the skin) |
| insulin aspart | DRUG | 0.2 U/kg body weight injected subcutaneously (under the skin) |
Inclusion Criteria: * Type 1 diabetes mellitus for more than 12 months * Treated with multiple daily insulin injections or continuous subcutaneous insulin infusion (CSII) for more than 12 months * Body mass index (BMI) between 18.0-28.0 kg/m2 (both inclusive) Exclusion Criteria: * Subject who has...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| FibroBiologics, Inc. | FBLG | 1 | PHASE1 | Undisclosed |
| MiMedx Group, Inc. | MDXG | 2 | N/A | Undisclosed |
| Integra LifeSciences Holdings Corporation | IART | 1 | N/A | Undisclosed |
| Organogenesis Holdings, Inc. Class A | ORGO | 1 | N/A | Undisclosed |
| Healthcare Services Group, Inc. | HCSG | 1 | N/A | Undisclosed |
NN1218 is an investigational small molecule being developed by Novo Nordisk for the treatment of diabetes. It was studied in a Phase 1 clinical trial in subjects with type 1 diabetes. The drug is still in clinical development and is not approved for use.
NN1218 is being developed by Novo Nordisk A/S, a biopharmaceutical company listed on the stock exchange under the ticker NVO. The company is conducting clinical research on this investigational drug for diabetes.
NN1218 is in Phase 1 clinical development. A Phase 1 trial investigating the drug in subjects with type 1 diabetes has been completed. The drug is investigational and has not been approved by regulatory authorities.
NN1218 has one completed Phase 1 clinical trial, registered as NCT01121289. The trial, titled 'A Trial Investigating NN1218 in Subjects With Type 1 Diabetes,' enrolled 26 participants in Germany. The study was randomized, double-blind, and active-controlled.
NN1218 is the investigational name for this drug candidate. No alternative names have been disclosed in the clinical trial information. The drug is being studied under the name NN1218 in the context of diabetes treatment.